Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19
Trends in Medical Sciences · 2022
DOI: 10.5812/tms-130706 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Medical Sciences, 2022. Verfasst von Pouya Safarzadeh Kozani und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kozani, P. S., Sheikhi, M., Baharifar, N., Shokoohi, S. D., Sheikhi, S., Mirarefin, S. M. J., Kozani, P. S., & Sheikhi, A. (2022). Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19. Trends in Medical Sciences. https://doi.org/10.5812/tms-130706
Vancouver
Kozani PS, Sheikhi M, Baharifar N, Shokoohi SD, Sheikhi S, Mirarefin SMJ, et al. Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19. Trends in Medical Sciences. 2022. doi:10.5812/tms-130706
BibTeX
@article{Kozani2022,
author = {Kozani, Pouya Safarzadeh and Sheikhi, Mehdi and Baharifar, Narges and Shokoohi, Setareh Dashti and Sheikhi, Sara and Mirarefin, Seyed Mohamad Javad and Kozani, Pooria Safarzadeh and Sheikhi, Abdolkarim},
title = {Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19},
journal = {Trends in Medical Sciences},
year = {2022},
doi = {10.5812/tms-130706}
}
EUVIMED